Insights

Strategic Growth Focus WuXi Advanced Therapies is positioned for significant growth through its recent acquisition by Altaris and planned merger with Minaris, creating a comprehensive global CDMO platform that offers broad development and manufacturing capabilities. This expansion opens avenues for sales of advanced biomanufacturing solutions, technology upgrades, and integrated service packages targeting the combined company's evolving needs.

Innovative Technology Edge The company's development of proprietary technologies such as TESSA™ and a robust CAR-T platform illustrates its commitment to cutting-edge cell therapy solutions. Sales opportunities exist in providing advanced testing equipment, process optimization tools, and scale-up technologies to support their continued innovation and commercialization efforts.

Collaborative Partnerships WuXi Advanced Therapies has established strategic alliances with major pharmaceutical companies like Janssen and biotech firms such as Interius BioTherapeutics, indicating a strong pipeline of collaborative projects. This creates potential sales channels for partnership integration tools, manufacturing services, and specialized bioprocessing technologies that cater to successful partner programs.

Market Leadership Potential Given its recognition through awards like the Manufacturing Tech Disruptor of the Year and its active positioning in high-growth areas such as cell and gene therapy, WuXi Advanced Therapies is a key player poised for increased market share. Companies offering innovative, differentiated solutions to enhance production efficiency or accelerate timelines could find lucrative sales opportunities here.

Market Expansion Opportunities With a global footprint, ongoing collaborations, and a focus on reducing costs and time-to-market for therapies, WuXi Advanced Therapies represents a viable target for sales of global supply chain solutions, manufacturing technologies, and regulatory compliance services aimed at scaling production across diverse geographic markets, including North America, Europe, and Asia.

WuXi Advanced Therapies Tech Stack

WuXi Advanced Therapies uses 8 technology products and services including Site Kit, Open Graph, jQuery, and more. Explore WuXi Advanced Therapies's tech stack below.

  • Site Kit
    Analytics
  • Open Graph
    Content Management System
  • jQuery
    Javascript Libraries
  • Prism
    Javascript Libraries
  • jQuery Migrate
    Javascript Libraries
  • Swiper
    Javascript Libraries
  • ActiveCampaign
    Marketing Automation
  • Priority Hints
    Performance

Media & News

WuXi Advanced Therapies's Email Address Formats

WuXi Advanced Therapies uses at least 1 format(s):
WuXi Advanced Therapies Email FormatsExamplePercentage
First.Last@advancedtherapies.comJohn.Doe@advancedtherapies.com
84%
FLast@advancedtherapies.comJDoe@advancedtherapies.com
15%
First@advancedtherapies.comJohn@advancedtherapies.com
1%

Frequently Asked Questions

Where is WuXi Advanced Therapies's headquarters located?

Minus sign iconPlus sign icon
WuXi Advanced Therapies's main headquarters is located at 4701 League Island Boulevard Philadelphia, Pennsylvania 19112 United States. The company has employees across 3 continents, including North AmericaAsiaEurope.

What is WuXi Advanced Therapies's official website and social media links?

Minus sign iconPlus sign icon
WuXi Advanced Therapies's official website is advancedtherapies.com and has social profiles on LinkedIn.

How much revenue does WuXi Advanced Therapies generate?

Minus sign iconPlus sign icon
As of April 2026, WuXi Advanced Therapies's annual revenue is estimated to be $500K.

What is WuXi Advanced Therapies's SIC code NAICS code?

Minus sign iconPlus sign icon
WuXi Advanced Therapies's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does WuXi Advanced Therapies have currently?

Minus sign iconPlus sign icon
As of April 2026, WuXi Advanced Therapies has approximately 132 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Chief Operations Officer: R. F.Owner: J. D.Director Of Clinical Manufacturing Ops - Cell & Gene Therapy: I. I.. Explore WuXi Advanced Therapies's employee directory with LeadIQ.

What industry does WuXi Advanced Therapies belong to?

Minus sign iconPlus sign icon
WuXi Advanced Therapies operates in the Biotechnology Research industry.

What technology does WuXi Advanced Therapies use?

Minus sign iconPlus sign icon
WuXi Advanced Therapies's tech stack includes Site KitOpen GraphjQueryPrismjQuery MigrateSwiperActiveCampaignPriority Hints.

What is WuXi Advanced Therapies's email format?

Minus sign iconPlus sign icon
WuXi Advanced Therapies's email format typically follows the pattern of First.Last@advancedtherapies.com. Find more WuXi Advanced Therapies email formats with LeadIQ.

When was WuXi Advanced Therapies founded?

Minus sign iconPlus sign icon
WuXi Advanced Therapies was founded in 2004.

WuXi Advanced Therapies

Biotechnology ResearchPennsylvania, United States51-200 Employees

Advanced Therapies is a cell therapy Contract Testing, Development and Manufacturing Organization (CTDMO.) We leverage our significant experience and proven track record in development and manufacturing, as well as expert testing services, to enable advanced therapies to be developed, manufactured and released faster and with greater predictability, thereby reducing the complexities and cost of high-touch, multi-vendor production models. 
On 7 March 2025, Advanced Therapies U.S. and our discovery arm, OXGENE (www.oxgene.com) were purchased by Altaris, an investment firm headquartered in the U.S. with an exclusive focus on the healthcare industry. With a 20+ year track record that includes 11 medical product CDMOs, Altaris is well-positioned to support Advanced Therapies over its next phase of growth. 
This transaction builds on Altaris’ strategic initiative for the cell and gene therapy market, which is focused on delivering life-changing therapies to patients at scale. As part of this strategy, Altaris acquired Minaris Regenerative Medicine (“Minaris”) from Resonac Holdings Corporation in January of this year. Minaris is a cell therapy contract development and manufacturing organization (CDMO) with operations in the United States, Germany and Japan.
Altaris intends to combine Advanced Therapies and Minaris into a single company, Minaris Advanced Therapies. The combined company’s extensive track record, breadth of capabilities and global manufacturing footprint will enhance our ability to service our customers, accelerate development timelines, reduce manufacturing costs, and improve patient access to life-saving treatments.
For now, Minaris and Advanced Therapies will continue to operate as two independent companies to ensure business continuity until the completion of certain separation milestones from their respective former parent companies. We expect them to be fully combined by the end of 2025.

Section iconCompany Overview

Headquarters
4701 League Island Boulevard Philadelphia, Pennsylvania 19112 United States
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2004
Employees
51-200

Section iconFunding & Financials

  • $50M$100M

    WuXi Advanced Therapies's revenue is estimated to be in the range of $50M$100M

Section iconFunding & Financials

  • $50M$100M

    WuXi Advanced Therapies's revenue is estimated to be in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.